3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
5
Breast Neoplasms
5
Ovarian Neoplasms
4
Pancreatic Neoplasms
3
Colorectal Neoplasms, Hereditary Nonpolyposis
3
Triple Negative Breast Neoplasms
2
Neoplastic Syndromes, Hereditary
2
Hereditary Breast and Ovarian Cancer Syndrome
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Urogenital Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Neoplasms, Unknown Primary
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Fanconi Anemia, Complementation Group D1
1
Digestive System Neoplasms
1
Cytopenia
1
Congenital Bone Marrow Failure Syndromes
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Intraductal, Noninfiltrating
1
Cancer Risk Syndrome
1
Breast Neoplasms, Male
1
Interventions
aldesleukin
42
Sunitinib
39
Cyclophosphamide
30
Nivolumab
27
Everolimus
27
pembrolizumab
26
Interferon-alpha
25
Bevacizumab
22
Sorafenib
21
Interleukin-2
20
fludarabine phosphate
19
Filgrastim
18
Ipilimumab
17
Radiotherapy
16
Axitinib
16
Peripheral Blood Stem Cell Transplantation
15
Gemcitabine
15
cabozantinib
14
fludarabine
11
Radiosurgery
11
Doxorubicin
11
Carboplatin
11
temsirolimus
10
Etoposide
9
Chemotherapy, Adjuvant
9
sargramostim
8
belzutifan
8
atezolizumab
8
Fluorouracil
8
pazopanib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Kidney Neoplasms
×
Genetic Counseling
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled